Supplementary Table 3. Logistic regression analysis to determine variables associated with good responders to SGLT2 inhibitors in overall patients

Variable	Odds ratio	95% CI	P value
Univariate			
Age, yr	0.99	0.97–1.00	0.125
Female sex	1.06	0.71–1.58	0.772
Body mass index, kg/m^2	1.03	0.98–1.08	0.265
Duration of diabetes, yr	0.98	0.96–1.00	0.092
Subtype of SGLT2 inhibitor (dapagliflozin)	1.04	0.64–1.70	0.878
Baseline HbA1c, %	1.50	1.25–1.80	<0.001
Baseline FPG, mg/dL	1.01	1.00–1.01	0.016
Baseline HOMA-β	1.00	0.98–1.03	0.667
Baseline HOMA-IR	1.44	0.96–2.17	0.077
Baseline eGFR, mL/min/1.73 m^2	1.01	1.00–1.02	0.139
No insulin therapy	1.56	1.03–2.35	0.035
Multivariate			
Baseline HbA1c, %	1.84	1.48–2.29	<0.001
No insulin therapy	2.91	1.77–4.78	<0.001

SGLT2, sodium-glucose cotransporter-2; CI, confidence interval; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; HOMA-β, homeostasis model assessment of β-cell function; HOMA-IR, homeostasis model assessment of insulin resistance; eGFR, estimated glomerular filtration rate.